Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer #worldlungcancerday https://t.co/A2MoOLtbox

https://t.co/gPC2SoFG5I

@Dr_R_Kurzrock https://t.co/gPC2SoXgXg

@AndresFCardonaZ @ivybelkins https://t.co/gPC2SoFG5I

@apipervallillo @JCO_ASCO @EGFRResisters @LeciaSequist @ZPiotrowskaMD https://t.co/gPC2SoFG5I

@mathew_carter1 @team_lung @ICR_London @royalmarsdenNHS is running Defactinib (FAK) trial, so it should be available not only in #UK, but worldwide. https://t.co/gPC2SoFG5I

RT @CrozrX: @AngeloDipa_ @ASCO_pubs @OncoAlert @ONcotwITting https://t.co/gPC2SoFG5I

RT @CrozrX: @AngeloDipa_ @ASCO_pubs @OncoAlert @ONcotwITting https://t.co/gPC2SoFG5I

RT @CrozrX: @AngeloDipa_ @ASCO_pubs @OncoAlert @ONcotwITting https://t.co/gPC2SoFG5I

RT @CrozrX: @AngeloDipa_ @ASCO_pubs @OncoAlert @ONcotwITting https://t.co/gPC2SoFG5I

@AngeloDipa_ @ASCO_pubs @OncoAlert @ONcotwITting https://t.co/gPC2SoFG5I

@jsoriamd @CCR_AACR https://t.co/gJ12WVNg1j

RT @CrozrX: @Dr_R_Kurzrock FAK inhibitor Defactinib is another promising approach. https://t.co/QJy0u3YJWu

RT @CrozrX: @Dr_R_Kurzrock FAK inhibitor Defactinib is another promising approach. https://t.co/QJy0u3YJWu

@LeciaSequist https://t.co/QJy0u3YJWu

@Dr_R_Kurzrock FAK inhibitor Defactinib is another promising approach. https://t.co/QJy0u3YJWu

@APassaroMD @CCR_AACR @AdamJSchoenfeld @EGFRResisters @EgfrUk @EGFRSummit @OncoAlert OSI/ Defactinib (FAK) is a promising option to explore. Also, Defactinib/ Pembrolizumab combo is investigated in a clinical trial. #cancer #treatment #resistance https://

@Tony_Calles @DrSanjayPopat Defactinib / OSI combo! https://t.co/gJ12WVvF9L

@s_couraud @DrSanjayPopat @DanaFarber @OncoAlert Defactinib / OSI combo https://t.co/gJ12WVvF9L

@APassaroMD @JackWestMD @n8pennell @DrSanjayPopat @VivekSubbiah @Alfdoc2 @drgandara @Tony_Calles @Jbauml @NarjustDumaMD https://t.co/gJ12WVvF9L

@JordiRemon @g_mountzios Defactinib / OSI combo https://t.co/gJ12WVvF9L

@n8pennell Defactinib / OSI may be a potential improvement https://t.co/gJ12WVNg1j

@drgandara https://t.co/QJy0u3YJWu

@JacobPlieth Make it even better!! Osi/ Defactinib! https://t.co/QJy0u3YJWu

@n8pennell Any chance at some point we may see Defactinib(FAK) / Osi combo? https://t.co/QJy0u3YJWu

@RenoHemonc @g_mountzios @OncoAlert @lcsmchat @myESMO As AC/DC song says, Money Talks! In case of targeted drug therapy #EGFR #NSCLC, although Osimertinib is clinically efficacious, acquired resistance to it is inevitable. I'd like to see this combo in a

@weoncologists @NEJM Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@PatelOncology @LeciaSequist @TheUSONetwork @EGFRResisters Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@DrRiyazShah @NHSEngland Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@jsoriamd Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@jillfeldman4 @ASCO @ivybelkins @EGFRResisters @LeciaSequist @JSabari @Jbauml @HelenaYu923 @CEC_Onc Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@BairdAM @JackWestMD @EgfrUk @EGFRResisters Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@Tony_Calles @JackWestMD Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u4gkO2

@JNCCN Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@geoff_oxnard @yonsei_u @JanssenUS @CD_AACR Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@CharuAggarwalMD @DrSteveMartin @ZPiotrowskaMD @JSabari @EGFRResisters Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@StephenVLiu Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

@EGFRResisters Defactinib / Osimertinib to overcome EGFR/TKI resistance https://t.co/QJy0u3YJWu

RT @CrozrX: Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired #EGFR-#TKI #resistance in non-small cell lung cancer…

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired #EGFR-#TKI #resistance in non-small cell lung cancer e#NSCLC #Defactinib #FAK #Osimertinib #Tagrisso #treatment #Lung #cancer @VerastemOncolog @danwpaterson @FDAOncology @myESMO ht

@drgandara https://t.co/hrUIycX4Ye Osimertinib/Defactinib way better! Looking forward to Defactinib/CH5126766 (MEK) data presentation 1H2020, and lastly FAK inhibitor advantage for potential therapeutic method to combat cancer dissemination via vascular ro

@megtirrell @SquawkCNBC https://t.co/hrUIycX4Ye Any plans for Defactinib/Osimertinib(Tagrisso) combo to overcome EGFR-TKI resistance? Tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer htt

@JacobPlieth @Vantageanalysis https://t.co/hrUIycX4Ye What they really need! https://t.co/GSYFaGoTky

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer https://t.co/A2MoOLbzZX

#respiratoryresearch Protein tyrosine kinase 2: a novel therapeutic target to overcome… https://t.co/0tsueCLGiJ